TU-2100

CAS No. 207972-39-2

TU-2100( —— )

Catalog No. M34452 CAS No. 207972-39-2

TU-2100 is an ethyl salicylate-containing compound with potential anti-acne effects for the study of acne.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    TU-2100
  • Note
    Research use only, not for human use.
  • Brief Description
    TU-2100 is an ethyl salicylate-containing compound with potential anti-acne effects for the study of acne.
  • Description
    TU-2100 is an ethyl salicylate-containing compound with potential anti-acne effects for the study of acne.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    207972-39-2
  • Formula Weight
    484.54
  • Molecular Formula
    C27H32O8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OCC)C=1C=CC=CC1OC(=O)CCCCCCCC(=O)OC=2C=CC=CC2C(=O)OCC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Crilvastatin

    Crilvastatin (PMD 387) is a novel, non-competitive hydroxymethylglutaryl coenzyme A reductase inhibitor with cholesterol-lowering activity, inhibiting cholesterol uptake in rats with hereditary hypercholesterolemia.

  • Glyasperin A

    Glyasperin A has cytotoxic properties against P-388 cells, its IC50 values being 6.0 microM.

  • S-Y048

    S-Y048 is an Oxoeicosanoid (OXE) receptor antagonist that inhibits allergen-induced eosinophil infiltration into the skin of experimentally sensitized rhesus monkeys to house dust mites and inhibits lung inflammation caused by aerosolized allergen challenge.